Who Owns Nanjing King-Friend Biochemical Pharmaceutical Company?

Nanjing King-Friend Biochemical Pharmaceutical Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Really Owns Nanjing King-Friend Biochemical Pharmaceutical?

Understanding the Nanjing King-Friend Biochemical Pharmaceutical SWOT Analysis requires a deep dive into its ownership structure. Discovering the key players behind a company reveals its strategic direction and potential for growth. This exploration uncovers the evolution of King-Friend ownership, from its founding to its current status as a major player in the biochemical pharmaceutical industry.

Founded in 2000, this Chinese pharmaceutical company has become a global force, specializing in heparin products. With a market capitalization of approximately CN¥18.76 billion as of June 12, 2025, understanding the King-Friend company ownership is crucial for investors and industry observers alike. This analysis will examine the impact of its IPO, major shareholders, and recent strategic shifts to provide a comprehensive view of its ownership profile.

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd., a significant player in the biochemical pharmaceutical sector, was established on October 16, 2000. The company's early days were marked by a clear vision: to become a world-class biopharmaceutical entity focused on integrated pharmaceutical internationalization. Understanding the initial ownership structure of the Nanjing King-Friend Biochemical Pharmaceutical is key to grasping its trajectory.

While the complete roster of founders and their original equity distribution isn't fully available in public records, Yongqun Tang is identified as the Legal Representative and General Manager. This suggests a pivotal role in the company's inception and early management. The company's commitment to innovation and international expansion has been a constant feature since its founding.

The early financial backing for the company included a Series A funding round in April 2011. This round involved investments from entities like Vivo Capital, Matrix, Eight Roads Ventures, and Matrix Partners China. Although the specific amount remains undisclosed, this initial funding from institutional investors was crucial for fueling early growth and development. The involvement of venture capital firms highlights a strategic alignment to support the company's expansion within the biochemical pharmaceutical industry.

Key Investors and Early Funding

The Series A funding round in April 2011 was a pivotal moment for Nanjing King-Friend Biochemical Pharmaceutical. The involvement of venture capital firms such as Vivo Capital, Matrix, and Eight Roads Ventures provided essential capital for early growth. These investors likely saw the potential for significant returns in the biochemical pharmaceutical market.

• Vivo Capital: A healthcare-focused investment firm.
• Matrix Partners: Known for investing in technology and healthcare companies.
• Eight Roads Ventures: The global venture arm of Fidelity International.
• Matrix Partners China: The China-focused arm of Matrix Partners.

Nanjing King-Friend Biochemical Pharmaceutical SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The evolution of King-Friend ownership began with its initial public offering (IPO) on July 19, 2017. The company, Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd., listed on the Shanghai Stock Exchange under the symbol 603707. The IPO offered 63.50 million shares at 7.21 CNY each. This marked a significant shift, transforming the company from a privately held entity to a publicly traded one, opening it up to a broader range of investors and subjecting it to increased regulatory scrutiny.

As of June 11, 2025, the company's market capitalization is approximately $2.61 billion, with 1.62 billion shares outstanding. The company's history includes strategic moves, such as the acquisition of a majority stake in Meitheal Pharmaceuticals by Hong Kong King-Friend Industrial Company, a subsidiary, for $95 million in 2019. This acquisition demonstrates the company's commitment to expanding its global presence and product offerings. Understanding the Competitors Landscape of Nanjing King-Friend Biochemical Pharmaceutical can offer further context to its strategic direction.

The current King-Friend ownership structure is characterized by a mix of institutional and individual investors. Key institutional investors include Invesco Great Wall Fund Management Co. Ltd., Bank of Communications Schroder Fund Management Co., Ltd., and HuaAn Fund Management Co., Ltd. Ju Hua Xie is the largest individual shareholder, holding a significant stake. Additionally, Vanguard funds hold positions, reflecting the company's appeal to both domestic and international investors. The presence of these diverse shareholders indicates a broad base of support for the biochemical pharmaceutical company.

Key Takeaways on King-Friend Ownership

The ownership of Nanjing King-Friend Biochemical Pharmaceutical Company is a mix of institutional and individual investors.

• The company went public in 2017.
• Ju Hua Xie is the largest individual shareholder.
• Vanguard funds also hold shares.
• The market cap is approximately $2.61 billion as of June 2025.

Nanjing King-Friend Biochemical Pharmaceutical PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The current board of directors of Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. includes key individuals in leadership positions. Yong Qun Tang serves as the Chairman and General Manager. Other board members include Xi Wei Huang, who is also the Board Secretary and Deputy General Manager, and Ju Hua Xie. Independent directors are Guoqing Cui and Yi Jin. The Chairman of the Supervisory Board is Zuqing Liu. Understanding the composition of the board is crucial for assessing the governance and strategic direction of the biochemical pharmaceutical company.

The board's structure, combining executive and independent directors, aims to balance internal expertise with external oversight. This structure is typical for publicly listed companies and is designed to ensure accountability and effective decision-making. For more insights into the company's strategic direction, you might find the Growth Strategy of Nanjing King-Friend Biochemical Pharmaceutical article helpful.

The voting structure at Nanjing King-Friend, like most publicly listed companies on the Shanghai Stock Exchange, is generally one-share-one-vote. While specific details on special voting rights are not publicly disclosed, the significant shareholding by major individuals like Ju Hua Xie, who holds approximately 27% of the shares, suggests substantial influence on company decisions. There have been no widely publicized proxy battles or activist campaigns in recent times. This ownership structure is a key aspect of understanding the King-Friend ownership and its impact on the company's direction.

Understanding Voting Power

The voting structure at Nanjing King-Friend is primarily based on one-share-one-vote, typical for companies listed on the Shanghai Stock Exchange.

• Major shareholders, such as Ju Hua Xie with a 27% stake, have significant influence.
• The board's composition, with both executive and independent directors, ensures a balance of expertise and oversight.
• Understanding the voting dynamics is crucial for assessing the company's governance and strategic direction.
• No recent proxy battles or activist campaigns have been reported.

Nanjing King-Friend Biochemical Pharmaceutical Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

In the past few years, Nanjing King-Friend Biochemical Pharmaceutical has shown strategic growth, including adjustments to its ownership profile. A notable move was the announcement of an equity buyback for CNY 40 million worth of shares. Additionally, in May 2025, the company secured loan support for A-share repurchase funds, indicating active share management strategies.

Key strategic initiatives included the licensing of biosimilars by its subsidiary, Hong Kong King-Friend Industrial Company (HKF), from Meitheal Pharmaceuticals in October 2024. This agreement allows HKF to market and distribute three biosimilars in the U.S., including medications like pegfilgrastim and filgrastim. This follows HKF's 2019 acquisition of a majority stake in Meitheal Pharmaceuticals for $95 million, establishing Meitheal as NKF's exclusive U.S. commercialization arm. These actions highlight NKF's efforts to broaden its global market presence and diversify its product offerings through strategic partnerships and acquisitions, shaping the King-Friend ownership landscape.

Industry trends suggest an increase in institutional ownership within the pharmaceutical sector. For Nanjing King-Friend Biochemical Pharmaceutical, institutional holdings by funds such as Vanguard Total International Stock Index Fund Investor Shares and Vanguard Emerging Markets Stock Index Fund Investor Shares have been observed, with some fluctuations in their ownership percentages. As of May 30, 2025, a total of 20 funds or institutions reported positions in the company. While the average portfolio weight dedicated to NKF Pharma increased by 119.19% over the last quarter, total shares owned by institutions decreased by 24.64% to 1,764K shares during the same period. The company's collaborative efforts, such as joint BLA submissions with Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd., on pegfilgrastim, also reflect a trend toward collaborative development and market expansion.

Key Development

Equity buyback program for CNY 40 million.

Strategic Partnership

HKF licensed biosimilars from Meitheal Pharmaceuticals.

Ownership Trend

Total shares owned by institutions decreased by 24.64%.

Collaborative Initiatives

Joint BLA submissions with other companies.

Nanjing King-Friend Biochemical Pharmaceutical Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs